Camargo Strengthens Research Team and Therapeutic Expertise
News Jul 24, 2014
Camargo Pharmaceutical Services has expanded its research team and therapeutic expertise with the addition of Dr. Wen-Yee Choi, Dr. Jillian Orans, Dr. Vien Lai and Kathryn Kemme.
Choi and Orans completed Camargo’s spring 2014 postdoctoral internship program and now join the company as research scientists. Choi specializes in cardiovascular medicine, including cardiac regeneration and bench-to-bedside research.
Her work on microRNA stem cell research is featured in numerous publications and presentations and is the subject of a pending patent, “Methods of Increasing Gene Expression Through RNA Protection.”
Orans has extensive experience in DNA mismatch repair in hereditary colon cancer, bacterial fitness and pathogenesis in infectious disease, and excels in using macromolecular crystallography to study the structural biology and biochemistry of proteins and nucleic acids.
Lai also joins Camargo as a research scientist with a focus on stem cell research and cardiovascular disease. His post-graduate training is focused on clinical medicine - specifically internal medicine, acute and emergency medicine, oncology and cardiovascular surgery.
As associate director of chemistry, manufacturing and control (CMC), Kemme provides direction and technical support for partnering contract manufacturing organizations. She has repeatedly conducted successful preapproval inspection readiness audits and gap analysis, and is proficient in project management, product transfer initiatives and scale-up.
“These individuals expand our capabilities and depth of skill in key therapeutic areas,” said Ken Phelps, president and CEO. “More so than ever, our team has the extensive knowledge and background needed to provide effective development solutions to our clients.”
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.